Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$0.04 - $0.13 $34 - $111
860 Added 3.48%
25,597 $1,000
Q2 2023

Jul 21, 2023

BUY
$0.43 - $0.65 $1 - $2
4 Added 0.02%
24,737 $12,000
Q1 2023

May 15, 2023

BUY
$0.46 - $0.81 $1,129 - $1,989
2,456 Added 11.02%
24,733 $15,000
Q4 2022

Feb 10, 2023

SELL
$0.5 - $261.0 $1,980 - $1.03 Million
-3,960 Reduced 15.09%
22,277 $14,000
Q3 2022

Nov 03, 2022

BUY
$1.04 - $322.5 $52 - $16,125
50 Added 0.19%
26,237 $45,000
Q2 2022

Aug 15, 2022

BUY
$0.41 - $1.24 $122 - $372
300 Added 1.16%
26,187 $32,000
Q1 2022

May 16, 2022

SELL
$0.62 - $1.17 $912 - $1,721
-1,471 Reduced 5.38%
25,887 $17,000
Q4 2021

Feb 11, 2022

SELL
$1.09 - $1.89 $340 - $589
-312 Reduced 1.13%
27,358 $30,000
Q3 2021

Nov 10, 2021

BUY
$1.44 - $2.73 $2,609 - $4,946
1,812 Added 7.01%
27,670 $50,000
Q2 2021

Aug 04, 2021

SELL
$2.63 - $3.67 $5,365 - $7,486
-2,040 Reduced 7.31%
25,858 $68,000
Q1 2021

Apr 30, 2021

SELL
$2.82 - $5.6 $3,220 - $6,395
-1,142 Reduced 3.93%
27,898 $100,000
Q4 2020

Jan 29, 2021

SELL
$2.09 - $3.09 $2,090 - $3,090
-1,000 Reduced 3.33%
29,040 $73,000
Q2 2020

Jul 23, 2020

SELL
$2.2 - $3.71 $12,117 - $20,434
-5,508 Reduced 15.49%
30,040 $99,000
Q1 2020

May 05, 2020

BUY
$1.9 - $4.98 $4,750 - $12,450
2,500 Added 7.56%
35,548 $87,000
Q4 2019

Jan 30, 2020

SELL
$3.95 - $5.35 $198,574 - $268,955
-50,272 Reduced 60.34%
33,048 $156,000
Q3 2019

Nov 01, 2019

SELL
$4.13 - $6.94 $28,084 - $47,192
-6,800 Reduced 7.55%
83,320 $357,000
Q2 2019

Jul 26, 2019

BUY
$3.98 - $6.2 $59,700 - $93,000
15,000 Added 19.97%
90,120 $525,000
Q1 2019

Apr 24, 2019

BUY
$2.0 - $4.4 $29,848 - $65,665
14,924 Added 24.79%
75,120 $289,000
Q4 2018

Feb 01, 2019

SELL
$1.61 - $3.62 $16,752 - $37,666
-10,405 Reduced 14.74%
60,196 $113,000
Q3 2018

Oct 25, 2018

SELL
$2.26 - $3.27 $45 - $65
-20 Reduced 0.03%
70,601 $226,000
Q2 2018

Jul 20, 2018

BUY
$3.02 - $4.94 $3,020 - $4,940
1,000 Added 1.44%
70,621 $213,000
Q1 2018

Apr 18, 2018

SELL
$3.46 - $5.14 $719 - $1,069
-208 Reduced 0.3%
69,621 $273,000
Q4 2017

Jan 17, 2018

BUY
$4.0 - $6.54 $40,632 - $66,433
10,158 Added 17.02%
69,829 $289,000
Q3 2017

Oct 17, 2017

BUY
$4.99 - $6.57 $297,758 - $392,038
59,671
59,671 $366,000

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $458M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.